Skip to main content
Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Lifespan care in SCD: Whom to transition, the patients or the health care system?
Transcranial doppler re-screening of subjects who participated in STOP and STOP II.
Fertility in transfusion-dependent thalassemia men: effects of iron burden on the reproductive axis.
Pain over time and its effects on life in thalassemia.
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Pregnancy outcomes in women with thalassemia in North America and the United Kingdom.
The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study.
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.